AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Closed 04-24 16:08:27

131.600

+1.200

+0.92%

High134.100	Low125.100	Vol11.62M
Open128.600	D1 Closing130.400	Amplitude6.90%
Mkt Cap121.20B	Tradable Cap121.20B	Total Shares921.00M
T/O1.51B	T/O Rate1.26%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":131.6,"timestamp":1777018107007,"preClose":130.4,"halted":0,"volume":11616653,"delay":0,"changeRate":0.009202453987729974,"floatShares":921000000,"shares":921000000,"eps":-1.4126633981916055,"marketStatus":"Closed","change":1.2,"latestTime":"04-24 16:08:27","open":128.6,"high":134.1,"low":125.1,"amount":1509889592,"amplitude":0.069018,"askPrice":131.6,"askSize":4000,"bidPrice":131.5,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":-1.4126633981916055,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":130.4,"openAndCloseTimeList":[[1776994200000,1777003200000],[1777006800000,1777017600000]],"volumeRatio":0.944519,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.6838,"impliedVolPercentile":0.9063},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2629883254","title":"BUZZ-HK-listed Akeso slides to 3-week low","url":"https://stock-news.laohu8.com/highlight/detail?id=2629883254","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629883254?lang=en_us&edition=fundamental","pubTime":"2026-04-23 15:50","pubTimestamp":1776930641,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed Akeso slides to 3-week low** Shares of antibody drugs developer Akeso Inc 9926.HK plunge 12.9% to HK$130, their lowest level since March 31** Stock on track for the biggest one-day pct decline since April 7, 2025; top pct loser in Hang Seng Biotech Index .HSBIO, which is down 4.1% ** Stock up nearly 15% in the last three weeks** \"Think it should be profit taking after Akeso confirmed LBA  in ASCO ,\" said Cui Cui, head of Asia Healthcare at Jefferies ** Onshore investors had been betting on positive data since early March, and the LBA suggests potentially positive results but inline with market expectations, Cui says** Nomura keeps \"neutral\" rating and lifts target price to HK$142.75 from HK$112.73, saying Akeso's ivonescimab is set to report overall survival  data from HARMONi-6 trial at ASCO annual meeting from May 29 to June 2 ** \"The results should be good,\" Nomura wrote, adding the LBA in the plenary-session status suggests that the OS data is most likely to be posit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260423:nL1N4160BT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516738.SGD","LU0561508036.HKD","IE00B543WZ88.USD","LU2778985437.USD","LU0417516571.SGD","LU0348766576.USD","IE00B5MMRT66.SGD","LU2488822045.USD","LU2476274308.USD","LU0634319403.HKD","LU0348827113.USD","LU0348767384.USD","LU1794554557.SGD","LU1961090484.USD","LU2399975544.HKD","LU0348735423.USD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0348783233.USD","LU2476274720.SGD","BK1574","LU0540923850.HKD","LU0348825331.USD","BK1161","09926","LU1720050803.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165196464","title":"HK Biotech Stocks Fell. Akeso Down 12%; Remegen, Zai Lab, KeyMed And Junshi Down 7%; Lepu And Innocare Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165196464","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165196464?lang=en_us&edition=fundamental","pubTime":"2026-04-23 11:32","pubTimestamp":1776915127,"startTime":"0","endTime":"0","summary":"HK biotech stocks fell. Akeso down 12%; Remegen, Zai Lab, KeyMed and Junshi down 7%; Lepu and Innocare down 6%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","02359","03759","02137","06606","06978","09606","03347","09995","02162","09926","02268","09688","09966","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184360495","title":"Stock Track | AKESO Plummets 5.69% Intraday as Fundamental Concerns Overshadow Positive Clinical Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1184360495","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184360495?lang=en_us&edition=fundamental","pubTime":"2026-04-23 09:40","pubTimestamp":1776908440,"startTime":"0","endTime":"0","summary":"AKESO's stock plummeted 5.69% during intraday trading, giving back gains from the previous session.The sharp decline comes despite the recent release of positive Phase II clinical data for its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629146045","title":"Is It Too Late To Consider Akeso (SEHK:9926) After Strong Five Year Share Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2629146045","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629146045?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:20","pubTimestamp":1776856803,"startTime":"0","endTime":"0","summary":"If you are wondering whether Akeso shares still offer value after a strong run, the numbers behind the current price deserve a closer look.\nAt a last close of HK$149.30, Akeso has delivered returns of 1.3% over 7 days, 33.2% over 30 days, 31.8% year to date and 60.7% over 1 year, with a very large 3 year gain and 173.2% over 5 years.\nThese moves have put Akeso on the radar of investors trying to understand what is already priced in and what may still be up for grabs. Recent coverage has...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-it-too-late-to-consider-akeso-sehk9926-after-strong-five","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/is-it-too-late-to-consider-akeso-sehk9926-after-strong-five","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0634319403.HKD","DCF","LU2399975544.HKD","LU2778985437.USD","LU0417516902.SGD","LU0348825331.USD","LU0348735423.USD","LU1961090484.USD","IE00B543WZ88.USD","LU0348783233.USD","LU0561508036.HKD","LU2488822045.USD","LU0348766576.USD","LU0540923850.HKD","LU1794554557.SGD","LU0348767384.USD","LU2476274308.USD","BK1574","LU1720050803.USD","IE00BPRC5H50.USD","LU2476274720.SGD","09926","LU0417516738.SGD","BK1161","IE00B5MMRT66.SGD","LU0348784397.USD","LU0348827113.USD","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101728190","title":"AKESO Shares Climb Nearly 3% on Positive Phase II Data for Cadonilimab Combo in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1101728190","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101728190?lang=en_us&edition=fundamental","pubTime":"2026-04-22 10:36","pubTimestamp":1776825408,"startTime":"0","endTime":"0","summary":"AKESO (09926) saw its shares rise by nearly 3%. As of the time of writing, the stock was up 2.66%, trading at HK$150.6 with a turnover of HK$613 million. The increase follows the company's...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","BK1574","LU2476274720.SGD","LU0348827113.USD","LU2778985437.USD","VXUS","IE00B5MMRT66.SGD","BK1161","LU0417516902.SGD","LU0561508036.HKD","LU0348825331.USD","LU0540923850.HKD","LU0348784397.USD","BK4585","LU2476274308.USD","LU1720050803.USD","LU0417516571.SGD","LU0634319403.HKD","IE00BPRC5H50.USD","LU1961090484.USD","LU0417516738.SGD","09926","LU0348783233.USD","LU1794554557.SGD","BK4588","LU2488822045.USD","LU0348735423.USD","IE00B543WZ88.USD","LU0348767384.USD","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629706348","title":"Akeso says cadonilimab-chemo extends OS past 23 months in phase 2 pancreatic cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629706348","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629706348?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:54","pubTimestamp":1776740090,"startTime":"0","endTime":"0","summary":"Akeso reported Phase II COMPASSION-26 results for cadonilimab with chemotherapy in first-line advanced pancreatic cancer, already presented at AACR 2026.Data showed improved survival outcomes, with strongest benefit in locally advanced disease.Study also indicated broad tumor control across overall population, with similar response patterns in locally advanced and metastatic patients.Safety profile remained manageable, with no new safety concerns flagged.Update reinforces Akeso strategy to expand cadonilimab use into hard-to-treat tumors, supporting its longer-term growth outlook in oncology immunotherapy.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260421:nNDL62fwjK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU2476274720.SGD","LU1720050803.USD","LU2488822045.USD","LU0540923850.HKD","LU0561508036.HKD","IE00B543WZ88.USD","LU2778985437.USD","LU2476274308.USD","LU1961090484.USD","LU2399975544.HKD","BK1574","LU0348767384.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0348766576.USD","LU0417516571.SGD","LU0348783233.USD","LU0417516738.SGD","LU0348827113.USD","LU0348825331.USD","IE00BPRC5H50.USD","LU0348735423.USD","LU0348784397.USD","BK1161","LU0417516902.SGD","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124678664","title":"China International Capital Corporation: National Policy Optimizes Initial Pricing Mechanism for Innovative Drugs, Pharmaceutical Sector Set for High-Quality Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1124678664","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124678664?lang=en_us&edition=fundamental","pubTime":"2026-04-16 14:39","pubTimestamp":1776321543,"startTime":"0","endTime":"0","summary":"China International Capital Corporation (CICC) has released a research report stating that on April 14th, the General Office of the State Council issued the \"Several Opinions on Improving the Drug...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274308.USD","01276","LU0359202008.SGD","LU2242644610.SGD","06160","LU0359201612.USD","LU1961090484.USD","BK1583","LU0348825331.USD","LU1251922891.USD","LU0348784397.USD","LU2488822045.USD","09606","IPOS","LU0561508036.HKD","LU0359201885.HKD","HK0000500386.USD","BK1161","01801","LU0348827113.USD","LU0348735423.USD","HK0000165453.HKD","HK0000252152.HKD","LU1969619763.USD","IE00B543WZ88.USD","BK1588","LU2778985437.USD","LU2476274720.SGD","BK1500","LU2328871848.SGD","06978","LU1023057109.AUD","BK1574","IE00BPRC5H50.USD","LU0307460666.USD","LU0417516902.SGD","LU1770034418.SGD","LU0588546209.SGD","HK0000252160.HKD","LU2097828631.EUR","IE00B5MMRT66.SGD","LU0455707207.USD","LU0348783233.USD","LU2399975544.HKD","159992","LU0502904849.HKD","09926","LU0348767384.USD","LU0417516738.SGD","LU1719994722.HKD","06990","LU0348766576.USD","BK1589","LU0417516571.SGD","LU0540923850.HKD","LU1303224171.USD","LU2097828557.USD","BK1191","LU0634319403.HKD","LU2097828474.EUR","LU2543165471.USD","LU0196878994.USD","LU2097828714.EUR","LU1720050803.USD","LU2097828805.USD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151797975","title":"Stock Track | Akeso Soars 5.08% Intraday on Strong Earnings and Sector Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=1151797975","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151797975?lang=en_us&edition=fundamental","pubTime":"2026-04-15 13:05","pubTimestamp":1776229514,"startTime":"0","endTime":"0","summary":"Akeso's stock surged 5.08% during intraday trading on Wednesday, reflecting significant investor optimism.The sharp rise follows the company's release of strong annual financial results, which showed...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627437953","title":"Assessing Akeso (SEHK:9926) Valuation After Positive Lung Cancer Data At 2026 European Lung Cancer Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2627437953","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627437953?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:16","pubTimestamp":1776078980,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) has come into focus after presenting new lung cancer data at the 2026 European Lung Cancer Congress. The company updated investors on cadonilimab and ivonescimab across difficult non small cell lung cancer settings.\nSee our latest analysis for Akeso.\nFollowing the ELCC updates, Akeso's HK$137.8 share price sits on the back of a 25.05% 1 month share price return and 21.62% year to date share price return. The 1 year total shareholder return of 58.48% and 3 year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-positive-lung-cance","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/assessing-akeso-sehk9926-valuation-after-positive-lung-cance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BPRC5H50.USD","LU0348767384.USD","LU0417516738.SGD","LU0561508036.HKD","LU2399975544.HKD","LU1720050803.USD","LU0348825331.USD","LU2778985437.USD","LU0417516571.SGD","09926","IE00B5MMRT66.SGD","LU2488822045.USD","BK1161","LU0348783233.USD","LU0417516902.SGD","LU2476274308.USD","LU0348784397.USD","LU0348735423.USD","LU1961090484.USD","LU1794554557.SGD","LU2476274720.SGD","LU0540923850.HKD","BK1574","LU0634319403.HKD","LU0348766576.USD","LU0348827113.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115393621","title":"AKESO Keeps Share Count Steady at 921.14 Million in March, Confirms Public Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1115393621","media":"Bulletin Express","labels":["SGX","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115393621?lang=en_us&edition=fundamental","pubTime":"2026-04-08 17:21","pubTimestamp":1775640101,"startTime":"0","endTime":"0","summary":"Akeso, Inc. (AKESO) filed its Monthly Return with Hong Kong Exchanges and Clearing on 08 April 2026, detailing equity movements for the month ended 31 March 2026. Akeso’s authorised share capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137745093","title":"Guojin Securities Maintains \"Buy\" Rating on AKESO (09926) as Clinical Trials Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1137745093","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137745093?lang=en_us&edition=fundamental","pubTime":"2026-04-07 16:56","pubTimestamp":1775552197,"startTime":"0","endTime":"0","summary":"Guojin Securities has issued a research report stating that AKESO's (09926) core products are experiencing rapid commercial scaling in the domestic market and possess the potential to lead global...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09926","LU0540923850.HKD","LU2778985437.USD","LU0348825331.USD","BK1161","LU0634319403.HKD","LU0348784397.USD","LU0561508036.HKD","LU2488822045.USD","LU0348783233.USD","LU0348827113.USD","LU0348735423.USD","IE00B543WZ88.USD","LU1961090484.USD","LU2476274308.USD","LU0417516738.SGD","LU1720050803.USD","LU0417516902.SGD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU0348767384.USD","LU2399975544.HKD","IE00BPRC5H50.USD","LU0348766576.USD","LU2476274720.SGD","LU1794554557.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625989657","title":"Akeso says cadonilimab combo posts 7-month median PFS in resistant NSCLC study","url":"https://stock-news.laohu8.com/highlight/detail?id=2625989657","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625989657?lang=en_us&edition=fundamental","pubTime":"2026-04-07 11:29","pubTimestamp":1775532569,"startTime":"0","endTime":"0","summary":"Akeso presented updated results at ELCC 2026 on April 6, 2026 from a Phase Ib/II trial of cadonilimab combined with anlotinib plus docetaxel in PD-1 inhibitor-resistant advanced non-small cell lung cancer.Study showed clinically meaningful anti-tumor activity with durable disease control, supporting potential positioning as a second-line option in a hard-to-treat setting.Benefit was described as consistent across key patient subgroups, indicating broader commercial reach if confirmed in later-stage studies.Safety profile was characterized as manageable, with no treatment-related deaths reported.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL8jv8VF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU1720050803.USD","LU2778985437.USD","LU0348783233.USD","LU2476274720.SGD","LU2399975544.HKD","LU0348827113.USD","LU0634319403.HKD","LU2488822045.USD","LU0348784397.USD","LU0348735423.USD","09926","LU0348825331.USD","LU1794554557.SGD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348767384.USD","LU0417516571.SGD","IE00BPRC5H50.USD","LU0417516902.SGD","BK1161","BK1574","LU0561508036.HKD","LU2476274308.USD","LU0348766576.USD","LU1961090484.USD","LU0417516738.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625127622","title":"Akeso (SEHK:9926) Valuation Check After New HARMONi-2 Quality Of Life And Survival Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2625127622","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625127622?lang=en_us&edition=fundamental","pubTime":"2026-04-06 10:17","pubTimestamp":1775441828,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) is back in focus after new HARMONi-2 data at the 2026 European Lung Cancer Congress showed its PD-1/VEGF antibody ivonescimab improved both progression-free survival and health-related quality of life versus pembrolizumab.\nSee our latest analysis for Akeso.\nThe new HARMONi-2 data and recent China approvals are landing alongside strong momentum, with a 30-day share price return of 30.94% and a 1-year total shareholder return of 63.56%, pointing to rising investor risk...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-new-harmoni-2-quality-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-new-harmoni-2-quality-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348825331.USD","LU2778985437.USD","LU0348735423.USD","IE00B5MMRT66.SGD","LU1720050803.USD","LU0348783233.USD","IE00B543WZ88.USD","LU2476274308.USD","LU0348766576.USD","LU2399975544.HKD","LU0417516738.SGD","LU1961090484.USD","IE00BPRC5H50.USD","BK1161","LU2488822045.USD","LU1794554557.SGD","LU0348767384.USD","LU0561508036.HKD","LU0634319403.HKD","LU0540923850.HKD","LU2476274720.SGD","LU0417516571.SGD","LU0348827113.USD","LU0417516902.SGD","LU0348784397.USD","09926","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172541363","title":"China International Capital Corp. Highlights Positive Trends in Domestic Innovative Drug Sector, Anticipates Key Academic Developments in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1172541363","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172541363?lang=en_us&edition=fundamental","pubTime":"2026-04-03 10:54","pubTimestamp":1775184869,"startTime":"0","endTime":"0","summary":"According to statistics from the NMPA and PharmaGO, the total business development value for domestic innovative drugs in the first quarter of 2026 exceeded $60 billion, surpassing the full-year 2024...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1251922891.USD","LU2778985437.USD","LU0348735423.USD","09995","LU0348827113.USD","LU0588546209.SGD","LU0307460666.USD","159992","LU1969619763.USD","BK1515","LU0417516738.SGD","LU2399975544.HKD","09926","06938","BK1574","LU0634319403.HKD","LU0348825331.USD","IE00BPRC5H50.USD","LU0561508036.HKD","BK1588","01276","LU0348766576.USD","LU2476274308.USD","LU2476274720.SGD","BK1161","LU1794554557.SGD","LU1303224171.USD","01877","06978","LU0359201885.HKD","IE00B5MMRT66.SGD","LU0359201612.USD","LU0359202008.SGD","BK1191","LU2488822045.USD","LU2543165471.USD","LU0348784397.USD","LU0540923850.HKD","LU0417516902.SGD","LU2328871848.SGD","LU1770034418.SGD","LU1023057109.AUD","LU0348783233.USD","IE00B543WZ88.USD","LU1719994722.HKD","LU1720050803.USD","BK1500","BK1583","LU0348767384.USD","LU1961090484.USD","06160","LU0417516571.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124816078","title":"Stock Track | AKESO Soars 5.53% Intraday on Positive Phase III Quality-of-Life Results for Ivonescimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1124816078","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124816078?lang=en_us&edition=fundamental","pubTime":"2026-04-01 11:40","pubTimestamp":1775014801,"startTime":"0","endTime":"0","summary":"AKESO's stock price surged 5.53% during intraday trading on Wednesday, following the release of encouraging clinical data for its flagship oncology drug.The company presented patient-reported...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624530051","title":"Akeso says ivonescimab improves quality of life vs pembrolizumab in Phase III NSCLC study","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530051?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:40","pubTimestamp":1774989618,"startTime":"0","endTime":"0","summary":"Akeso presented health-related quality-of-life results from Phase III HARMONi-2 at ELCC 2026 for ivonescimab versus Merck’s Keytruda in first-line PD-L1-positive non-small cell lung cancer.Patient-reported outcomes indicated ivonescimab improved overall well-being and daily functioning versus Keytruda in chemotherapy-free treatment.Symptom measures showed better control of key lung cancer symptoms, with a sustained advantage in breathing-related complaints.Akeso positioned findings as supportive of broader uptake, citing prior HARMONi-2 efficacy results that outperformed Keytruda in a head-to-head study.Ivonescimab has been marketed in China since 2025 for this setting, strengthening Akeso’s push to establish it as a new standard of care.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL7F4bc7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0348767384.USD","LU1961090484.USD","LU2488822045.USD","BK1161","IE00B543WZ88.USD","LU0348825331.USD","LU0634319403.HKD","LU2778985437.USD","LU0540923850.HKD","LU2476274308.USD","LU0348735423.USD","LU0348784397.USD","LU0417516902.SGD","LU0348827113.USD","LU0561508036.HKD","BK1574","09926","IE00BPRC5H50.USD","LU1794554557.SGD","LU0348766576.USD","LU2476274720.SGD","LU0348783233.USD","LU0417516738.SGD","LU1720050803.USD","LU0417516571.SGD","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170199647","title":"Mainland Investors Divest HK$2.47 Billion from Hong Kong Market, Offloading ETFs and Oil Stocks While Boosting Tencent Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=1170199647","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170199647?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:03","pubTimestamp":1774865038,"startTime":"0","endTime":"0","summary":"On March 30, mainland capital recorded a net sell-off of HK$2.467 billion in the Hong Kong stock market. Specifically, the Shanghai-Hong Kong Stock Connect saw net purchases of HK$1.667 billion,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0541501648.USD","LU0143863198.USD","LU0326948709.USD","LU1048588211.SGD","LU1224444064.USD","LU0516422440.USD","LU0140636845.USD","LU0061477393.USD","LU1807302812.USD","LU2462611646.USD","LU1880383440.USD","IE0031814852.USD","LU0985320562.USD","LU1568876251.USD","LU0738912210.USD","LU0054450605.USD","LU1725190679.HKD","LU1235295612.USD","LU2125910849.SGD","03317","LU0293314216.USD","LU0348825331.USD","LU1691799644.USD","LU0737861772.HKD","LU1242518931.SGD","LU0502904849.HKD","LU0084288322.USD","LU1051769294.HKD","LU0251144936.SGD","LU0828237940.HKD","LU0329678170.USD","LU0456846285.SGD","LU1251922891.USD","LU0070217475.USD","LU0700851271.USD","SG9999003461.SGD","LU2237443549.SGD","TCEHY","LU2251237306.USD","LU0128522744.USD","LU0828238088.HKD","LU0328353924.USD","LU0359201612.USD","LU1868837565.USD","LU1282651048.USD","LU1048484197.HKD","LU0543330483.HKD","LU0456842615.SGD","IE00BQXX3D17.EUR","SG9999002463.SGD","00700","LU0509642566.USD","LU1960683339.HKD","LU0254981946.USD","LU0203347892.USD","LU0175139822.USD","LU1323998911.USD","SGXZ31699556.SGD","IE00B067MR52.USD","LU0431992006.USD","BK1238","LU1102505929.USD","LU0345769128.USD","LU0791591158.USD","LU0823041008.USD","LU0067412154.USD","IE0032834883.USD","GB00BDT5M118.USD","LU0054237671.USD","IE00B3M56506.USD","LU0918141705.HKD","LU0593848301.USD","LU0029874905.USD","LU0320764243.SGD","LU1211504680.USD","LU0210527791.USD","LU0348783233.USD","LU0605514214.HKD","LU0211977185.USD","LU0650527681.SGD","LU1642822792.SGD","LU0244354667.USD","LU1044875133.USD","IE0003895053.USD","IE0008368742.USD","LU0345769631.USD","LU1733274390.USD","IE00B8HQ1Z84.USD","LU1629966141.USD","LU1048596156.SGD","BK1526","SGXZ90724238.SGD","LU1226287529.USD","SG9999018857.SGD","SG9999000327.SGD","LU0823039010.USD","LU0011963245.USD","LU0072913022.USD","LU1226288097.SGD","LU1831875114.USD","LU0052750758.USD","LU0898667661.SGD","LU0096374516.USD","SGXZ51526630.SGD","LU0878005551.USD","IE00B29SXG58.USD","LU2778985437.USD","IE00BZ08YR35.GBP","BK4588","LU0634319403.HKD","LU0737861699.HKD","LU1282651121.HKD","LU0868486357.SGD","SG9999001226.SGD","LU0488056044.USD","LU0540923850.HKD","SG9999013353.USD","LU0541502299.USD","BK1531","LU1770034418.SGD","LU1044876610.USD","BK1528","LU2087589342.USD","IE00B0169N27.USD","LU0106959298.USD","LU1366334578.USD","BK4570","LU2237443382.USD","SG9999001903.USD","LU1951186391.HKD","IE00BZ08YS42.EUR","LU0417516738.SGD","LU0164880469.USD","LU0469268626.HKD","LU2237443895.HKD","BK1502","BK1607","LU1655091459.SGD","LU1810669033.SGD","IE00B543WZ88.USD","LU1046422090.SGD","IE00B031HY20.USD","LU2317271919.USD","LU2226246903.HKD","LU0149721374.USD","IE0008368411.USD","LU0029875118.USD","LU0269904917.USD","LU0229945570.USD","LU0873338254.USD","LU0051755006.USD","LU1051768304.USD","LU0823413587.USD","BK1615","LU0043850808.USD","LU0039217434.USD","LU0048597586.USD","LU0499858438.USD","IE0032431581.USD","LU0320764599.SGD","LU0441854154.USD","LU2051468812.USD","LU0611395673.USD","BK4585","LU0642271901.SGD","LU0261947096.USD","LU0359202008.SGD","LU1152091168.USD","LU2279701549.SGD","SG9999002562.SGD","LU1064130708.USD","LU0463099449.HKD","LU0633140727.USD","LU0348735423.USD","LU0708995583.HKD","SG9999014674.SGD","LU0348814723.USD","LU0348816934.USD","LU0886674414.USD","LU0196878994.USD","LU2152927971.USD","SG9999017495.SGD","03033","IE00BF5LJ272.USD","LU2008162690.USD","BK1516","IE00BQXX3C00.GBP","LU0589944569.HKD","LU0821914370.USD","HK0001040168.HKD","HTCD.SI","LU1008478684.HKD","LU1282649141.HKD","LU0370786039.SGD","BK1618","IE00B0JY6N72.USD","LU0211331839.USD","LU0117844026.USD","LU1196710864.SGD","BK1608","LU0210526637.USD","LU0228367735.SGD","LU0683595622.HKD","LU0080751232.USD","LU0107464264.USD","LU2476274720.SGD","HK0000352382.USD","HSTECH","LU1152091754.HKD","LU0594300179.USD","LU2097828557.USD","HK0000306701.USD","SG9999014880.SGD","IE00BQXX3F31.USD","LU1366334651.USD","LU2399975544.HKD","LU0823426308.USD","LU0169518387.USD","LU0577902298.EUR","BK1517","LU1804176565.USD","LU0648948544.HKD","LU2257852520.SGD","LU0672654166.SGD","LU0823426480.USD","LU0348827113.USD","LU1770036033.HKD","LU0348784397.USD","LU0210533765.USD","LU2362540622.SGD","LU0173614495.USD","LU0345776255.USD","LU2237443622.USD","LU0396098781.USD","LU0456827905.SGD","LU2251237488.HKD","SG9999001689.USD","LU2476274308.USD","LU0561508036.HKD","SG9999000459.SGD","SG9999015978.USD","LU0588545904.SGD","LU0320764755.SGD","LU1733274473.HKD","LU1023057109.AUD","LU2045819591.USD","LU0072462343.USD","IE00BGV7N243.SGD","LU0417516902.SGD","LU0823038988.USD","LU0128522157.USD","LU0823397285.USD","LU1515016050.SGD","LU1105468828.SGD","LU2237443465.HKD","LU0314109678.HKD","LU1188198961.HKD","IE0003851619.USD","LU1688375341.USD","LU2097828474.EUR","IE00B5MMRT66.SGD","LU0289960550.SGD","LU2449936058.SGD","LU0531971595.HKD","SG9999006597.SGD","LU0784639295.USD","HK0000914660.USD","LU1974910355.USD","LU1868837722.USD","LU1993786604.SGD","LU0307460666.USD","LU1224709979.USD","LU0572944931.SGD","HK0000320223.HKD","LU0235996351.USD","LU0577902538.SGD","LU1044874839.SGD","LU1226288253.USD","BK4504","LU0501845795.SGD","LU0831103253.SGD","LU2125910500.SGD","BK1609","LU0326950275.SGD","LU1769817096.USD","LU0708995153.HKD","LU0164865239.USD","LU0455707207.USD","LU0228659784.USD","LU1794554557.SGD","HK0000306685.HKD","LU0315178854.USD","LU0675040207.SGD","LU1328615791.USD","LU0049112450.USD","LU2265009873.SGD","LU1196710195.USD","LU2293587155.HKD","BK4550","LU0791590937.USD","LU2362541273.HKD","SG9999001846.SGD","LU2148510915.USD","LU0972618739.USD","LU0588545730.USD","LU2242644610.SGD","LU1956131251.USD","LU0106259558.USD","LU0882747503.HKD","LU1282649810.SGD","IE0034224299.USD","LU1883866441.USD","LU1328277881.USD","LU0348783662.USD","IE0001KFT4U8.USD","LU0516422952.EUR","LU0188438112.USD","LU0106252389.USD","BK1614","LU0203345920.USD","SGXZ99366536.SGD","HK0000352291.HKD","IE00B8L5B284.USD","LU1504937902.USD","LU0231483743.USD","LU0048580855.USD","LU1316542783.SGD","LU2362541513.USD","SG9999015945.SGD","LU0345775950.USD","LU0577902454.USD","LU0287142896.SGD","LU1718418525.SGD","LU1813983027.USD","LU2498475776.HKD","02800","LU0047713382.USD","LU0607220059.USD","LU2177674079.SGD","IE00B0169L03.USD","LU0577902611.USD","LU0608807946.USD","LU1102505762.USD","LU1734074674.USD","LU0516422366.SGD","HSI","LU1719994722.HKD","LU0117841782.USD","LU0127658192.USD","LU0862451753.SGD","IE0009570106.USD","LU1917777945.USD","LU0449509016.USD","LU1814569148.SGD","BK1610","BK1095","LU0143863784.USD","LU0823397103.USD","LU1303224171.USD","LU0261950983.USD","LU0588545490.SGD","SG9999015952.SGD","LU0572940350.SGD","LU0417516571.SGD","LU0327786744.USD","LU0577902371.SGD","LU2133065610.SGD","LU1568876335.HKD","LU0878004406.USD","LU1481107354.HKD","LU0499858602.USD","BK1521","IE0008369823.USD","LU1282649067.USD","BK1586","IE00B031HW06.USD","LU0163747925.USD","LU0880133367.SGD","LU2247934214.USD","LU0192582467.USD","BK1591","LU0572939691.SGD","LU0259732245.USD","LU1196710351.USD","80883","LU0823413660.USD","LU0164872284.USD","LU0588546209.SGD","LU0651946864.USD","LU0797268264.HKD","LU1226287875.USD","LU0329678337.USD","SG9999018865.SGD","LU1439102457.SGD","LU0414403682.SGD","LU2097828714.EUR","SG9999014914.USD","LU0348805143.USD","LU0181495838.USD","LU1808992512.USD","LU0049853897.USD","LU0819121731.USD","IE00B97KM107.HKD","SG9999014906.USD","LU0862451837.USD","LU1785774172.SGD","HK0000914686.HKD","LU2237443978.SGD","LU1769817179.HKD","SG9999015986.USD","LU1675838814.USD","BK1589","LU1439103000.SGD","BK4077","LU0048388663.USD","LU0264606111.USD","LU0865486749.SGD","HK0001040143.USD","LU0543330566.HKD","LU2097828805.USD","SG9999007991.SGD","LU0384037296.USD","LU0348723411.USD","LU0871576103.HKD","BK4581","LU0516423091.SGD","LU2097828631.EUR","LU1880383366.USD","LU1242518857.USD","LU0149534421.HKD","LU1226288170.HKD","LU0819123356.HKD","LU0918141887.USD","LU0531970944.HKD","09926","LU0132412106.USD","LU2039709279.SGD","LU0608807433.USD","BK1163","SG9999006514.SGD","SG9999001051.SGD","LU0823040885.USD","SG9999014898.SGD","IE00BZ08YT58.USD","LU1064131003.USD","SG9999000418.SGD","LU1226287792.SGD","LU1868838027.USD","SG9999001069.SGD","LU0890818403.SGD","LU2023250504.SGD","LU1282648689.USD","SG9999001093.SGD","IE0003795394.USD","LU3063872942.SGD","LU0165289439.USD","SGXZ81514606.USD","LU2106854487.HKD","LU0828237510.HKD","LU0856984785.SGD","LU0359201885.HKD","LU0651947912.USD","LU0633140560.USD","SG9999004220.SGD","LU0516423174.USD","SG9999002828.SGD","HK0000320264.USD","IE00B031J352.USD","LU0214875030.USD","LU1981816686.USD","LU0449515922.USD","LU0786609619.USD","IE00BPRC5H50.USD","LU0979878070.USD","LU0348788117.USD","LU0594300419.USD","LU1720050803.USD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622997804","title":"Akeso (SEHK:9926) FY 2025 Loss Deepens Despite 2H Revenue Growth Challenging Bullish Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2622997804","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622997804?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:13","pubTimestamp":1774653194,"startTime":"0","endTime":"0","summary":"Akeso (SEHK:9926) has reported FY 2025 results with second half revenue of C¥1.6b and a basic EPS loss of C¥0.60, while trailing 12 month revenue reached C¥3.1b against a net loss of C¥1.1b. The business has seen revenue move from C¥1.1b in 2H 2024 to C¥1.6b in 2H 2025, with basic EPS shifting from a loss of C¥0.32 to a loss of C¥0.60 over the same period, as investors weigh growth in the top line against persistent losses. Overall, the latest numbers point to expanding operations but...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-fy-2025-loss-deepens-despite-2h-revenue-growt","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-fy-2025-loss-deepens-despite-2h-revenue-growt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2488822045.USD","BLSX","LU1720050803.USD","LU1961090484.USD","LU2778985437.USD","LU1794554557.SGD","LU2476274720.SGD","IE00B543WZ88.USD","LU0348766576.USD","LU2399975544.HKD","BK4112","LU0634319403.HKD","LU0417516571.SGD","LU0417516738.SGD","LU0348784397.USD","09926","LU0417516902.SGD","LU0348735423.USD","LU0348825331.USD","BLSG","LU0348827113.USD","IE00BPRC5H50.USD","BK1574","LU0561508036.HKD","LU0348767384.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0540923850.HKD","BK1161","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622433688","title":"Akeso Widens Loss in 2025; Shares Climb 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622433688","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622433688?lang=en_us&edition=fundamental","pubTime":"2026-03-27 15:12","pubTimestamp":1774595544,"startTime":"0","endTime":"0","summary":"Akeso  widened its attributable loss for the year 2025 to 1.11 billion yuan from 514.5 million yuan a year prior, according to a Thursday Hong Kong bourse filing.Shares of the drug company were up nearly 3% in Friday afternoon trading.Loss per share stood at 1.23 yuan in the fiscal year, compared with 0.60 yuan in the previous corresponding year.Revenue jumped 44% to 3.06 billion yuan in the period from 2.12 billion yuan in the year-ago period, supported by the initial inclusion of cadonilimab and ivonescimab into the China National Reimbursement Drug List.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU1961090484.USD","LU0540923850.HKD","IE00BPRC5H50.USD","LU2476274308.USD","LU2476274720.SGD","LU2488822045.USD","LU0561508036.HKD","LU0348825331.USD","LU2399975544.HKD","BK1574","LU0348766576.USD","BK1161","LU0348735423.USD","LU0634319403.HKD","09926","LU2778985437.USD","LU0348827113.USD","LU0417516571.SGD","LU0417516738.SGD","LU1794554557.SGD","LU0348784397.USD","LU0348767384.USD","LU0348783233.USD","LU1720050803.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811748","title":"Press Release: Akeso Reports Full-Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811748","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622811748?lang=en_us&edition=fundamental","pubTime":"2026-03-27 11:54","pubTimestamp":1774583640,"startTime":"0","endTime":"0","summary":"HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc.   announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business.In 2025, Akeso achieved record commercial sales revenue of RMB3,033.1 million, a 51.48% year-on-year increase. All approved products and indications are now included in China's National Reimbursement Drug List . The strong commercial growth in 2025 was fueled by strong clinical validation and widespread adoption by both healthcare professionals and patients.By the end of 2025, several high-impact indications were added to the latest NRDL, including:. -- Cadonilimab: 1L gastric cancer and 1L cervical cancer. With stable pricing for core first-line  indications and improved hospital access, Akeso's commercial platform is positioned for a transformative 2026.As the world's first and only approved PD-1/VEGF bispecific antibody, ivonescimab solidified its global leadership in 2025 by iterating upon existing Standar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0634319403.HKD","LU0348767384.USD","LU0348735423.USD","LU1794554557.SGD","AI","LU2778985437.USD","LU0561508036.HKD","LU2476274720.SGD","BK4006","LU0417516902.SGD","BK4585","LU0348783233.USD","LU2399975544.HKD","LU0540923850.HKD","IE00BPRC5H50.USD","BK4588","BK4543","LU0348784397.USD","IE00B543WZ88.USD","AIPO","09926","BK4023","LU1961090484.USD","AIYY","CHAT","BK4551","BK1161","LU0417516571.SGD","LU0348766576.USD","LU1720050803.USD","LU2488822045.USD","AGIX","LU0348827113.USD","SOC","HCC","BK4587","BK1574","LU0417516738.SGD","BK4213","BK4528","LU2476274308.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.1248},{"period":"1month","weight":0.0867},{"period":"3month","weight":0.1193},{"period":"6month","weight":0.1319},{"period":"1year","weight":0.4037},{"period":"ytd","weight":0.154}],"compareEarnings":[{"period":"1week","weight":-0.0182},{"period":"1month","weight":0.034},{"period":"3month","weight":-0.0312},{"period":"6month","weight":-0.0094},{"period":"1year","weight":0.1741},{"period":"ytd","weight":0.0111}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.034604},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.003133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}